Date: 2011-09-19
Type of information: Licensing agreement
Compound: PI-2301
Company: Merck KGaA, Merck Serono (Germany) Peptimmune (USA)
Therapeutic area: Neurodegenerative diseases - Autoimmune diseases
Type agreement: licensing
development
commercialisation
Action mechanism:
Disease: mutliple sclerosis
Details: Merck KGaA has acquired worldwide exclusive rights to PI-2301, an experimental drug for multiple sclerosis, previously developed by Peptimmune Inc. PI-2301 has completed Phase 1b in multiple sclerosis and is ready to initiate phase 2 clinical trials. The acquisition of PI-2301 covers its worldwide exclusive development and commercialization rights. Merck KGaA will investigate the application of this product in autoimmune diseases such as multiple sclerosis.
Financial terms: Financial details of the agreement were not disclosed.
Latest news:
